Year 2015 (49)

Edition nr. 11

Policy prescriptions: the firepower of the EU pharmaceutical lobby

Industry, including the pharmaceutical industry, enjoys almost systematic and privileged access to the decision-making process in the European Union, facilitated by the huge amounts of money spent on lobbying activities, the variety of parties in ...

Read article

Efficacy of empagliflozin for cardiovascular disorders

Empagliflozin belongs to the new class of oral blood glucose lowering drugs, the SGLT2 inhibitors, and has been introduced on the market as the third drug in this class. As regards efficacy and side-effects, it does not differ substantially from ...

Read article

Ten myths about the pharmaceutical industry: myth 9

9. Avoid the use of generic drugs, as their strength varies. Gebu 2013; 47: 75-82 discussed that the principle of bioequivalence is generally accepted as a measure of the interchangeability of drugs, although some suggestions were made that could ...

Read article

Mercaptopurine/azathioprine and photosensitisation

Doctors prescribing mercaptopurine and pharmacists providing it should be aware that its use in combination with exposure to ultraviolet radiation can lead to phototoxic reactions. If they observe or suspect such reactions, they should report thi ...

Read article

Sponsorship bias in clinical trials

Joel Lexchin, the author of the translated article, indicates that the pharmaceutical industry is in a situation of conflict. The economic fate of pharmaceutical companies depends on the favourable outcomes of the trials they sponsor, which may m ...

Read article